Delivery of RNA and DNA therapeutics to the brain remains a major challenge due to the restrictive nature of the blood–brain barrier. Viral-based delivery approaches are limited by immunogenicity and challenges with repeat dosing, while intrathecal administration is invasive and may restrict dosing frequency and overall treatment flexibility.

TERP(Target-engineered Responsive Polymer) Technology : The next-generation polymer-lipid nanoparticle for safer non-viral delivery of RNAs to the targeted tissues and cells.

TERP Payloads

RNA DNA ASO siRNA mRNA
LNP and TERP nanoparticles comparison

Selective Tissue Targeting

With a library of components, the TERP nanoparticles can be customized to deliver payloads to the target tissues selectively.

Excellent Safety Profile

The non-immunogenic and biocompatible TERP formulation allows repeated dosing of biologicals at high therapeutic doses.

Payload Versatility

The unique properties of TERP chemistry allows loading a wide range of payloads, including RNAs, peptides & antibodies, and small molecules.

TERP technology enables:

  • Non-immunogenic systemic CNS delivery facilitating redosing and dose titration
  • Broad CNS distribution with access to deep brain regions
  • Large, flexible cargo supports plug-and-play deployment for multiple therapeutic strategies
Brain